261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

• DOI: 10.1016/j.esmoop.2024.103282
• Publication Date: 2024-05-17T11:21:24Z
• Authors: P. Schmid; M. Oliveira; J. O'Shaughnessy; M. Cristofanilli; S.L. Graff; S-A. Im; S. Loi; S. Saji; S. Wang; D.W. Cescon; T. Hovey; A. Nawrot; K. Tse; P. Vukovic; G. Curigliano